| abstract |
The invention concerns a marker for low-grade inflammation and/or low-grade inflammation-related diseases such as cardiovascular disease, ischemic heart disease and type 2 diabetes. More particularly it concerns the measurement of the concentration of soluble urokinase plasminogen activator receptor (suPAR) in human biological fluids (sputum, cystic fluid, ascites, serum, plasma, urine) as a tool of diagnosing and/or prognosticating low-grade inflammation and the risk of development of the related diseases such as cancer, cardiovascular disease, ischemic heart disease and type 2 diabetes. |